{"id":1021399,"date":"2026-11-16T11:22:13","date_gmt":"2026-11-16T16:22:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/"},"modified":"2026-11-16T11:22:13","modified_gmt":"2026-11-16T16:22:13","slug":"dare-bioscience-receives-approximately-852000-in-additional-grant-funding","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/","title":{"rendered":"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding"},"content":{"rendered":"<h2>\nAdditional funding represents the second-to-last anticipated payment under the up to approximately $10.7 million grant agreement supporting preclinical development of a novel non-hormonal intravaginal contraceptive<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212; Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women&#8217;s health between promising science and real-world solutions, today announced that it has received an additional payment of $851,796 under its existing grant agreement.<\/p>\n<p align=\"justify\">This payment represents the second-to-last anticipated tranche under the up to approximately $10.7 million grant agreement originally announced in November 2024. The grant funding is supporting Dar\u00e9 Bioscience&#8217;s ongoing research and development activities focused on identifying and developing a novel non-hormonal intravaginal contraceptive to address unmet needs among women in low- and middle-income country (LMIC) settings, particularly those seeking or preferring non-hormonal contraceptive options.<\/p>\n<p align=\"justify\">&#8220;We are grateful for the continued support of this important program and its commitment to expanding contraceptive options for women around the world,&#8221; said Sabrina Martucci Johnson, President and CEO of Dar\u00e9 Bioscience. &#8220;This additional funding will allow us to continue advancing our work toward a novel, non-hormonal intravaginal contraceptive that has the potential to address significant unmet needs and provide women with greater choice and autonomy in their reproductive health.&#8221;<\/p>\n<p align=\"justify\">Dar\u00e9 previously received approximately $5.4 million in initial funding under the grant agreement in 2024 in support of the ongoing Phase 3 clinical study of Ovaprene investigational hormone-free monthly contraceptive (ClinicalTrials.gov ID: NCT06127199) and an additional approximately $3.6 million payment in November 2025. Future funding under the agreement remains contingent upon achievement of additional milestones specified in the grant agreement.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>ABOUT DAR\u00c9 BIOSCIENCE, INC.<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Dar\u00e9 Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women\u2019s health between promising science and real-world solutions. Every innovation Dar\u00e9 Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Dar\u00e9 Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to \u201cwait it out\u201d or \u201clive with it,\u201d while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Dar\u00e9 Bioscience is working to change that. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wCuqQ6RxF1pTg4A_sSVmk9FZFCeBt5xj9APzvcA5g7lQIDSxU4Qc6zsUDuHrquEtWaVS5HRx5Vo7dNuVf1ohNKETe0ZWHDqy6EeKNDx3yK4=\" rel=\"nofollow\" target=\"_blank\">darebioscience.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>FORWARD-LOOKING STATEMENTS<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Dar\u00e9 Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cprepare,\u201d \u201cprogress,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cbuild\u201d or the negative version of these words and similar expressions.<\/p>\n<p align=\"justify\">In this press release, forward-looking statements include, but are not limited to, statements relating to: Dar\u00e9 Bioscience\u2019s anticipated use of grant funding; the potential for Dar\u00e9 Bioscience to receive an additional disbursement under the grant agreement; the anticipated impact of the grant funding on research and development of a potential non-hormonal intravaginal contraceptive; the potential for Dar\u00e9 Bioscience to develop a novel non-hormonal intravaginal contraceptive candidate suitable for and acceptable to women in LMIC settings, and the potential market opportunity for such a product, if successfully developed and approved for marketing.<\/p>\n<p align=\"justify\">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar\u00e9 Bioscience\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: advancing an early stage preclinical program through preclinical development and into human clinical trials; the risk that positive findings in preclinical studies and\/or early clinical studies of a product candidate may not be predictive of success in subsequent clinical and\/or nonclinical studies of that candidate; Dar\u00e9 Bioscience&#8217;s dependence on third parties to conduct nonclinical and clinical studies and manufacture and supply clinical trial material, and the performance and resource commitments of such third parties; difficulties in manufacturing drug product candidates and their components at the required quality, stability and scale for clinical trials and commercialization; Dar\u00e9 Bioscience&#8217;s ability to achieve the milestones and meet other requirements to receive additional funding under the grant agreement; Dar\u00e9 Bioscience&#8217;s ability to obtain additional capital when and as needed to execute its business strategy and continue as a going concern; dependence on grants and other financial awards from governmental entities and the foundation and the risk that funding may be reduced, delayed, or terminated, or may be insufficient to advance a product candidate into or through a particular stage of development as anticipated; potential suspension and delisting of Dar\u00e9 Bioscience&#8217;s common stock from The Nasdaq Capital Market; failure or delay in commencing, conducting or completing clinical trials and the inherent uncertainty of outcomes of clinical trials; the risk that positive findings in early clinical and\/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and\/or nonclinical studies of that candidate; Dar\u00e9 Bioscience&#8217;s ability to develop, obtain U.S. Food and Drug Administration or foreign regulatory approval for, and commercialize its product candidates and to do so on communicated timelines; the risk that Dar\u00e9 Bioscience&#8217;s product candidates may fail to demonstrate acceptable safety and tolerability or sufficient efficacy in clinical trials; Dar\u00e9 Bioscience&#8217;s ability to retain its licensed rights to develop and commercialize a product or product candidate; Dar\u00e9 Bioscience&#8217;s ability to satisfy the monetary obligations and other requirements in connection with its exclusive in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Dar\u00e9 Bioscience&#8217;s ability to adequately protect or enforce its, or its licensor\u2019s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Dar\u00e9 Bioscience&#8217;s product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Dar\u00e9 Bioscience&#8217;s products or product candidates or the business activities of Dar\u00e9 Bioscience, its commercial collaborators or other third parties on which Dar\u00e9 Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Dar\u00e9 Bioscience&#8217;s ability to raise additional capital or on Dar\u00e9 Bioscience&#8217;s operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar events that compromise Dar\u00e9 Bioscience&#8217;s technology systems and\/or significantly disrupt Dar\u00e9 Bioscience&#8217;s business or those of third parties on which Dar\u00e9 Bioscience relies.<\/p>\n<p align=\"justify\">Dar\u00e9 Bioscience\u2019s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar\u00e9 Bioscience\u2019s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Dar\u00e9 Bioscience\u2019s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar\u00e9 Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>\n        <strong>Dar\u00e9 Bioscience Investor Relations<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=o-ObZ9Ra26BFFRzvQHFo-J3C8gMVXleJ_tkOaS9fF-kvl-fjTyklJgqBd-vEptQJ1xO20IgTa89gixIy_ZQgaFGtouG-7VgkSePMLtvY1IbFdTJ8oKCyq50LSovIfbyE\" rel=\"nofollow\" target=\"_blank\">innovations@darebioscience.com<\/a>\n      <\/p>\n<p>\n        <em>Source: Dar\u00e9 Bioscience, Inc.<\/em>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2M3N2Q0YWYtZjJiYi00NGU3LWFjYTQtMzMxYmMwMTA3MThkLTEwMTk5MzctMjAyNi0xMS0xNi1lbg==\/tiny\/Dar-Bioscience-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Additional funding represents the second-to-last anticipated payment under the up to approximately $10.7 million grant agreement supporting preclinical development of a novel non-hormonal intravaginal contraceptive SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women&#8217;s health between promising science and real-world solutions, today announced that it has received an additional payment of $851,796 under its existing grant agreement. This payment represents the second-to-last anticipated tranche under the up to approximately $10.7 million grant agreement originally announced in November 2024. The grant funding is supporting Dar\u00e9 Bioscience&#8217;s ongoing research and development activities focused on identifying and developing a novel non-hormonal intravaginal contraceptive to address unmet &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021399","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Additional funding represents the second-to-last anticipated payment under the up to approximately $10.7 million grant agreement supporting preclinical development of a novel non-hormonal intravaginal contraceptive SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women&#8217;s health between promising science and real-world solutions, today announced that it has received an additional payment of $851,796 under its existing grant agreement. This payment represents the second-to-last anticipated tranche under the up to approximately $10.7 million grant agreement originally announced in November 2024. The grant funding is supporting Dar\u00e9 Bioscience&#8217;s ongoing research and development activities focused on identifying and developing a novel non-hormonal intravaginal contraceptive to address unmet &hellip; Continue reading &quot;Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T16:22:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding\",\"datePublished\":\"2026-11-16T16:22:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/\"},\"wordCount\":1296,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/\",\"name\":\"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=\",\"datePublished\":\"2026-11-16T16:22:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/","og_locale":"en_US","og_type":"article","og_title":"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding - Market Newsdesk","og_description":"Additional funding represents the second-to-last anticipated payment under the up to approximately $10.7 million grant agreement supporting preclinical development of a novel non-hormonal intravaginal contraceptive SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Dar\u00e9 Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women&#8217;s health between promising science and real-world solutions, today announced that it has received an additional payment of $851,796 under its existing grant agreement. This payment represents the second-to-last anticipated tranche under the up to approximately $10.7 million grant agreement originally announced in November 2024. The grant funding is supporting Dar\u00e9 Bioscience&#8217;s ongoing research and development activities focused on identifying and developing a novel non-hormonal intravaginal contraceptive to address unmet &hellip; Continue reading \"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T16:22:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding","datePublished":"2026-11-16T16:22:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/"},"wordCount":1296,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/","name":"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=","datePublished":"2026-11-16T16:22:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODM1MyM3OTY1OTIwIzIwMDgzNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-receives-approximately-852000-in-additional-grant-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dar\u00e9 Bioscience Receives Approximately $852,000 in Additional Grant Funding"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021399"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021399\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}